Patents by Inventor MARTIN WEISSER

MARTIN WEISSER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING FOR COMBINATION TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-CD79B ANTIBODY DRUG CONJUGATE
    Publication number: 20220380480
    Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.
    Type: Application
    Filed: April 29, 2022
    Publication date: December 1, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Katharina LECHNER, Thomas Francis MOORE, Martin WEISSER, Natalie DIMIER
  • DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY
    Publication number: 20220372156
    Abstract: The present invention relates to methods of treating a B-cell proliferative disorder by administering an anti-CD20/anti-CD3 bispecific antibody, and methods for reduction of adverse effects in response to the administration of the anti-CD20/anti-CD3 bispecific antibody. The present invention further relates to combination treatment methods of treating a B-cell proliferative disorder.
    Type: Application
    Filed: April 29, 2022
    Publication date: November 24, 2022
    Applicants: Hoffmann-La Roche Inc., Roche TCRC Inc.
    Inventors: Katharina LECHNER, Linda LUNDBERG, Thomas Francis MOORE, Peter MORCOS, Martin WEISSER, Marina BACAC, Martin BARRETT, Axel BOEHNKE, David CARLILE, Nassim DJEBLI
  • Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1 antibody after failure of anti-PD-L1/PD1 treatment
    Patent number: 11498968
    Abstract: The current invention relates to the combination therapy of an anti-CSF-1R antibody (especially a CSF-1R dimerization inhibitor) in combination with an anti-PD-L1 antibody after PD1/PD-L1 inhibitor treatment failure, corresponding pharmaceutical compositions or medicaments using such combination therapy.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: November 15, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael Cannarile, Anna-Maria Jegg, Francesca Michielin, Carola Ries, Dominik Ruettinger, Martin Weisser
  • Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1 antibody after failure of anti-PD-L1/PD1 treatment
    Publication number: 20190309078
    Abstract: The current invention relates to the combination therapy of an anti-CSF-1R antibody (especially a CSF-1R dimerization inhibitor) in combination with an anti-PD-L1 antibody after PD1/PD-L1 inhibitor treatment failure, corresponding pharmaceutical compositions or medicaments using such combination therapy.
    Type: Application
    Filed: June 11, 2019
    Publication date: October 10, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Michael CANNARILE, Anna-Maria JEGG, Francesca MICHIELIN, Carola RIES, Dominik RUETTINGER, Martin WEISSER
  • COMBINATION THERAPY OF ANTI-HER3 ANTIBODIES
    Publication number: 20160159912
    Abstract: The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies.
    Type: Application
    Filed: October 7, 2015
    Publication date: June 9, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Frieder Bauss, Birgit Bossenmaier, Thomas Friess, Christian Gerdes, Max Hasmann, Marlene Thomas, Martin Weisser
  • Combination therapy of anti-HER3 antibodies
    Patent number: 9180185
    Abstract: The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: November 10, 2015
    Assignee: Hoffman-La Roche Inc.
    Inventors: Frieder Bauss, Birgit Bossenmaier, Thomas Friess, Christian Gerdes, Max Hasmann, Marlene Thomas, Martin Weisser
  • COMBINATION THERAPY OF ANTI-HER3 ANTIBODIES
    Publication number: 20140227255
    Abstract: The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies.
    Type: Application
    Filed: January 9, 2014
    Publication date: August 14, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Frieder Bauss, Birgit Bossenmaier, Thomas Friess, Christian Gerdes, Max Hasmann, Marlene Thomas, Martin Weisser
  • CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) BIOMARKERS
    Publication number: 20140017230
    Abstract: The present application describes chronic lymphocytic leukemia (CLL) biomarkers. In particular, the invention concerns miRNA151 3p, miRNA409 3p, PTK2, and/or PI3K as biomarkers for patient selection in CLL, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, and methods of advertising related thereto.
    Type: Application
    Filed: February 1, 2013
    Publication date: January 16, 2014
    Applicants: HOFFMANN-LA ROCHE INC., GENENTECH, INC.
    Inventors: DAVID DORNAN, GUILLEMETTE DUCHATEAU-NGUYEN, TRI QUANG NGUYEN, GIUSEPPE PALERMO, MARTIN WEISSER, RU-FANG YEH